Learn How

Learn how AI can help to promote early identification of patients likely to experience a cost bloom, reduce the incidence and progression of chronic conditions, and avoid traditional risk scoring methods that fail to explicitly account for cost bloomers. Discover how AI can help to predict the low-cost patients most likely become cost bloomers, identify gaps in chronic condition management, and assess a wide variety of distinct and often overlooked patient data to identify rising risk.

Automatically ingest data from dozens of health data sources including...

Vital Signs

Data indicating the status of the body’s vital and life-sustaining functions, with core vital signs including blood pressure, pulse, respiration rate, and body temperature.

Medical Claims

Data extracted from health insurance medical claims with details about dates and place of service, diagnosis codes, key procedures, use of medical equipment, and provider specialties.

Lab Test Results

Data about important risk markers from tests used for diagnosis, monitoring therapy, or screening, with details about specific results and abnormal indicators.

nodes
Closedloop icon with a line

ClosedLoop generates explainable predictions using

thousands of auto generated, clinically relevant contributing factors

Mark Wilson
55-Year-Old Male
Risk of costs rising at least 50% in the next 12 months
Risk Score Percentile
90
Impact on Risk  |  Contributing Factor
Value
+21% | # of Distinct Providers (12M)
10
+16% | Pct Abnormal Lab Results
45%
+11% | Resting Heart Rate
90
+8% | Total # of Lab Tests (3M)
20

What Are Rising Risk and Cost Bloomers?

It is well documented that a small percentage of patients account for most of the healthcare expenditures in the United States; the costliest 10% of patients account for more than two-thirds of the healthcare expenditures in the United States.¹ What is less well known is that, while some high-cost patients have consecutively high-cost years, the majority experienced what has been termed a ‘cost bloom’—a dramatic year-over-year cost increase that moved them from lower expenditure deciles into the upper decile of spending. These previously low-cost patients account for roughly 68% of all high-cost patients annually.² 

Why It Matters

Proactively identifying such rising risk patients is especially important, as they may disproportionately benefit from interventions designed to mitigate future costs. Such efforts can be an effective way to simultaneously improve quality and reduce costs, and are distinct from programs that address the needs of existing high-cost patients.

Unfortunately, accurately identifying these rising risk patients can prove challenging for healthcare organizations (HCOs). Nearly 50% of cost bloomers are likely to have no inpatient hospital costs, and when compared to persistently high-cost patients, are diagnosed with four times fewer chronic conditions.²  

In addition, and to the extent that standard prediction tools and reimbursement formulas have failed to accurately predict or account for ‘cost bloomers,’ HCOs pay the price. Such models leave HCOs that are held accountable for the total cost of care vulnerable to inadequate funding, financial penalties, and unfair performance assessments, which can also ultimately affect the health outcomes for patients.² 

AI Presents an Opportunity

As HCOs invest to improve patient outcomes and avoid unnecessary costs, it is paramount they have the ability to anticipate and address the needs of rising risk patients. AI can help by accurately identifying patients likely to be cost bloomers. Using AI-based models can also avoid the drawbacks of traditional risk scoring by allowing providers to easily integrate a wide range of distinct and dynamic patient data that would otherwise have been excluded. By leveraging AI, HCOs can launch proactive interventions designed to address the needs of rising risk patients in ways that drive a disproportionate benefit in quality, costs and future health outcomes. 

Did You Know…

  • 25% of patients identified as low-cost move to a higher echelon of expenditure each year³ 
  • More than half of high-cost patients in a three-year analysis did not have high costs in the prior two years²
  • $28,468 is the annual mean expenditure for the top 10% of high-cost patients¹
expand_more
Citations & Footnotes

1 Wammes, Joost Johan Godert, et al. “Systematic review of high-cost patients' characteristics and healthcare utilisation.” BMJ open, vol. 8, no. 9, Sep. 2018. DOI: 10.1136/bmjopen-2018-023113. 

2 Tamang, Susan, Milstein, Arnold, et al. “Predicting patient ‘cost blooms’ in Denmark: a longitudinal population-based study.” BMJ open, vol. 7, no. 1, Jan. 2017. DOI: 10.1136/bmjopen-2016-011580.

3 Cohen, Steven B. “Statistical Brief #481 The Concentration and Persistence in the level of Health Expenditures over Time: Estimates for the U.S. Population, 2012-2013.” Agency for HealthCare Research and Quality, Sep. 2015. PMID: 28783282. Accessed on 12/11/2020.

Klas image

ClosedLoop.ai’s healthcare expertise was a big deal to us. It didn’t take a lot to translate things, and they adapted their approach to create a predictive model for our unique interest in the data streams.

Anonymous Customer CEO
KLAS Analyst Report
Cheryl

We are extremely impressed with the predictive modeling capabilities the ClosedLoop platform has delivered. The ClosedLoop team has exceeded all defined goals and benchmarks set to date and we anticipate a substantial return on our investment as these predictions are operationally deployed.

Cheryl Lulias
President & Executive Director, MHN
Klas image

We wanted to use the product for population health and SDOH. The things we can do with the ClosedLoop.ai product are unlimited.

Anonymous Customer
KLAS Analyst Report
image of Jim Walton

Over the course of my career, there has never been an opportunity like this. The need for efficiency is a daunting challenge. The capacity of predictive AI technology drives our efficiency and will have a lasting impact on our ability to help PCPs improve the quality of health outcomes while reducing health disparities.

Dr. Jim Walton
President & CEO, Genesis Physicians Group
image of Drew

ClosedLoop stood out from other AI firms in that they offered not only a usable, flexible analytics platform but extensive healthcare expertise.

Drew Crenshaw
Chief of Population Health, Oak Street Health

Learn What ClosedLoop Can Do for Your Organization

The industry’s best collection of customizable predictive models for common healthcare use cases.

Talk To An Expert